Eisai’s first investigational drug candidate from their drug discovery collaboration with University College London (UCL) is entering Phase I trials in Alzheimer’s disease (AD). The E2814 candidate, an anti-tau monoclonal antibody, will be assessed in its ability to slow the progression of AD. AD is a chronic, progressive, neurodegenerative disease characterized by formation of protein deposits known as plaques (made of amyloid-beta protein) and neurofibrillary tangles (made of tau prot...